Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells - Concepedia

Concepedia

Publication | Open Access

Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells

DOI Full Paper Access

76

Citations

27

References

2011

Year

Euphemia Leung, Ji Eun Kim, Gordon W. Rewcastle, Graeme J. Finlay, Bruce C. Baguley

Cancer Biology & Therapy

Abstract

Increased resistance to tamoxifen in these MCF-7 sub-lines is not associated with hypersensitivity to PI3K inhibitors. While both drugs inhibited AKT signaling, NVP-BEZ235 resembled rapamycin in inhibiting the mTOR pathway.

References

	Year	Citations
Sulforhodamine B colorimetric assay for cytotoxicity screening Vanicha Vichai, Kanyawim Kirtikara Nature Protocols Cytotoxicity ScreeningMedicineToxicologyToxicological AspectExperimental Toxicology	2006	3.6K
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt Kathryn O’Reilly, F. Rojo, Qing‐Bai She, Cancer Research	2006	2.5K
Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase Tommaso Simoncini, Ali Hafezi‐Moghadam, Derek P. Brazil, Nature Oestrogen ReceptorRegulatory SubunitSignal TransductionMolecular PhysiologyEndocrine Mechanism	2000	1.4K
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer Arkaitz Carracedo, Li Ma, Julie Teruya‐Feldstein, Journal of Clinical Investigation	2008	1.4K
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent <i>in vivo</i> antitumor activity Sauveur-Michel Maira, Frédéric Stauffer, Josef Brueggen, Molecular Cancer Therapeutics	2008	1.1K
Activation of Akt and eIF4E Survival Pathways by Rapamycin-Mediated Mammalian Target of Rapamycin Inhibition Shi-Yong Sun, Laura M. Rosenberg, Xuerong Wang, Cancer Research	2005	806
NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations Violeta Serra, Ben Markman, Maurizio Scaltriti, Cancer Research	2008	795
Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Paul Webb, Gabriela N. Lopez, Rosalie M. Uht, Molecular Endocrinology Estrogen ReceptorTamoxifen StimulationTranscriptional RegulationSignaling PathwayEstrogen Receptor/ap-1 Pathway	1995	662
Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor–positive human breast cancer Todd W. Miller, Bryan T. Hennessy, Ana M. González-Angulo, Journal of Clinical Investigation Breast OncologySignal TransductionPi3k PathwaysMedicineHormone Dependence	2010	536
AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer DSpace@MIT (Massachusetts Institute of Technology) Systems BiologyAkt-independent Signaling DownstreamOncogenic AgentMedicineTumor Suppressor	2009	535

Page 1